GMCSFs

GM-CSFs, or granulocyte-macrophage colony-stimulating factors, are a group of cytokines that stimulate the production, differentiation, and function of white blood cells, particularly granulocytes and macrophages. They act on hematopoietic progenitor cells and mature myeloid cells, and influence antigen presentation and inflammatory responses.

The gene CSF2 encodes GM-CSF. The GM-CSF receptor consists of an alpha subunit (CSF2RA) and a shared beta chain (CSF2RB) with other cytokine receptors. Signaling through the receptor activates pathways such as JAK-STAT and MAP kinase, leading to effects on cell survival, proliferation, and activation.

In hematopoiesis, GM-CSFs promote proliferation and differentiation of myeloid progenitors into neutrophils, eosinophils, and monocytes/macrophages. They also enhance the bactericidal and phagocytic functions of mature neutrophils and macrophages, and can aid in mobilizing hematopoietic stem cells into the bloodstream under certain conditions.

Clinically, recombinant human GM-CSF agents, most notably sargramostim, are used as hematopoietic growth factors to shorten chemotherapy- or transplant-associated neutropenia and to support stem-cell mobilization for autologous transplantation. They are also explored for roles in autoimmune and inflammatory conditions and as adjuvants in cancer therapy in specific settings.

Administration is typically subcutaneous or intravenous. Common adverse effects include bone pain, fever, edema, injection-site reactions, and leukocytosis. Rare but serious events can include capillary leak syndrome and hypersensitivity reactions. Caution is advised in patients with myeloid malignancies or active leukemia, as GM-CSF can stimulate malignant or inflammatory cells.

See also: G-CSF, CSF2 receptor, hematopoietic growth factors.